Kamada to Present at the Stifel 2025 Healthcare Conference
Kamada (NASDAQ: KMDA) announced that Amir London, Chief Executive Officer, will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 9:20 a.m. ET at the Lotte New York Palace Hotel in New York.
Mr. London will also be available for one-on-one investor meetings throughout the conference; investors should arrange meetings through their Stifel representative. A live webcast of the presentation will be available via the company-provided link.
Kamada (NASDAQ: KMDA) ha annunciato che Amir London, Chief Executive Officer, terrà una presentazione alla Stifel 2025 Healthcare Conference mercoledì, 12 novembre 2025 alle 9:20 ora orientale presso l'Hotel Lotte New York Palace a New York.
Il signor London sarà inoltre disponibile per incontri individuali con gli investitori durante la conferenza; gli investitori dovranno organizzare gli incontri tramite il loro rappresentante Stifel. Una diretta webcast della presentazione sarà disponibile tramite il link fornito dall'azienda.
Kamada (NASDAQ: KMDA) anunció que Amir London, director ejecutivo, participará en la Conferencia de Salud de Stifel 2025 el miércoles, 12 de noviembre de 2025 a las 9:20 a.m. ET en el hotel Lotte New York Palace en Nueva York.
El señor London también estará disponible para reuniones individuales con inversionistas durante la conferencia; los inversionistas deben coordinar las reuniones a través de su representante de Stifel. Habrá una retransmisión en vivo de la presentación a través del enlace proporcionado por la empresa.
Kamada (NASDAQ: KMDA)는 Amir London 최고경영자(CEO)가 Stifel 2025 Healthcare Conference에서 수요일, 2025년 11월 12일 동부 표준시 9:20에 뉴욕의 롯데 뉴욕 팔래스 호텔에서 발표할 것이라고 발표했습니다.
London 씨는 또한 컨퍼런스 기간 중 일대일 투자자 미팅도 가능하며, 투자자들은 Stifel 담당자를 통해 미팅을 주선해야 합니다. 회사에서 제공한 링크를 통해 발표의 라이브 webcast를 시청할 수 있습니다.
Kamada (NASDAQ: KMDA) a annoncé que Amir London, Directeur général, présentera lors de la Stifel 2025 Healthcare Conference mercredi 12 novembre 2025 à 9h20 HE à l'hôtel Lotte New York Palace à New York.
M. London sera également disponible pour des entretiens individuels avec des investisseurs pendant la conférence; les investisseurs doivent organiser les entretiens par l'intermédiaire de leur représentant Stifel. Une retransmission en direct de la présentation sera disponible via le lien fourni par la société.
Kamada (NASDAQ: KMDA) gab bekannt, dass Amir London, Chief Executive Officer, auf der Stifel 2025 Healthcare Conference am Mittwoch, 12. November 2025 um 9:20 Uhr MEZ im Lotte New York Palace Hotel in New York auftreten wird.
Herr London wird auch im Verlauf der Konferenz für Einzelgespräche mit Investoren zur Verfügung stehen; Investoren sollten Treffen über ihren Stifel-Vertreter arrangieren. Eine Live-Webcast der Präsentation wird über den vom Unternehmen bereitgestellten Link verfügbar sein.
Kamada (NASDAQ: KMDA) أعلنت أن أمير لندن، المدير التنفيذي، سيقدم في مؤتمر ستيفل للرعاية الصحية 2025 يوم الأربعاء، 12 نوفمبر 2025 في الساعة 9:20 صباحاً بتوقيت شرق الولايات المتحدة في فندق لوت نيويورك بالاس في نيويورك.
كما سيكون السيد لندن متاحاً أيضاً لعقد اجتماعات فردية مع المستثمرين طوال المؤتمر؛ يجب على المستثمرين ترتيب الاجتماعات من خلال ممثل ستيفل الخاص بهم. ستتوفر مشاهدة مباشرة لبث العرض عبر الرابط المقدم من الشركة.
Kamada (NASDAQ: KMDA) 宣布，首席执行官 Amir London 将在 Stifel 2025 Healthcare Conference 上发言，时间为 2025年11月12日 美国东部时间上午9:20，地点在纽约洛特大都会宫酒店。
伦敦先生也将于整个会议期间提供一对一的投资者会谈；投资者应通过其 Stifel 代表安排会谈。公司提供的链接将提供该演示的实时网络广播。
- None.
- None.
REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate in the Stifel 2025 Healthcare Conference, to be held to be held at the Lotte New York Palace Hotel, New-York, NY on November 11–13, 2025.
Mr. London is scheduled to present at 9:20 a.m. Eastern Time on Wednesday, November 12, 2025. In addition to the presentation, Mr. London will be available for one-on-one investor meetings throughout the conference. Investors interested in arranging a meeting should contact their Stifel representative.
A live webcast of the presentation at the Stifel 2025 Healthcare Conference is available at the following link:
https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/HjTbVTTY3Uga9gAArmdJZu
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
When will Kamada (KMDA) present at the Stifel 2025 Healthcare Conference?
How can investors schedule a one-on-one meeting with Kamada CEO at the Stifel 2025 Healthcare Conference?
Where is the Stifel 2025 Healthcare Conference taking place for the Kamada presentation?
Will Kamada (KMDA) provide a webcast of its Stifel 2025 Healthcare Conference presentation?
Who is presenting for Kamada (KMDA) at the Stifel 2025 Healthcare Conference?
What time zone is used for Kamada's Stifel 2025 Healthcare Conference presentation time?
